We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The agency must adjust the incremental cost from fiscal 2016 by the average amount costs rose in the three years before the current fiscal year. Read More
An FDA advisory committee voted 10 to 1 Wednesday that a muscular dystrophy drug candidate does not have enough supporting data to be considered effective. Read More